[HTML][HTML] Metformin activates AMPK through the lysosomal pathway
CS Zhang, M Li, T Ma, Y Zong, J Cui, JW Feng, YQ Wu… - Cell metabolism, 2016 - cell.com
Metformin (N, N-dimethylbiguanide) is the most widely used first-line drug for treatment of
type 2 diabetes (T2D). This anti-hyperglycemic drug offers clinical superiority over other
glucose-lowering drugs, with little induction of hypoglycemia or weight gain and with the
effects to reverse fatty liver, improve insulin sensitivity, and ameliorate cardiovascular
dysfunctions associated with T2D (extensively reviewed by
type 2 diabetes (T2D). This anti-hyperglycemic drug offers clinical superiority over other
glucose-lowering drugs, with little induction of hypoglycemia or weight gain and with the
effects to reverse fatty liver, improve insulin sensitivity, and ameliorate cardiovascular
dysfunctions associated with T2D (extensively reviewed by
Metformin (N, N-dimethylbiguanide) is the most widely used first-line drug for treatment of type 2 diabetes (T2D). This anti-hyperglycemic drug offers clinical superiority over other glucose-lowering drugs, with little induction of hypoglycemia or weight gain and with the effects to reverse fatty liver, improve insulin sensitivity, and ameliorate cardiovascular dysfunctions associated with T2D (extensively reviewed by
cell.com